Evenity (Romosozumab) Metabolism and Energy Expenditure

What Romosozumab Is and How It Works at the Molecular Level

Romosozumab is a monoclonal antibody that binds sclerostin, a glycoprotein secreted primarily by osteocytes. Sclerostin ordinarily suppresses Wnt/beta-catenin signaling in osteoblast precursors, keeping bone formation in check. Blocking sclerostin removes that brake, stimulating osteoblast differentiation and collagen matrix production while simultaneously reducing osteoclast activity through secondary RANKL-OPG pathway effects. The net result is a rapid, simultaneous rise in bone formation markers and fall in bone resorption markers, a profile unique among approved osteoporosis agents. [1]

The Wnt/Beta-Catenin Pathway and Its Metabolic Reach

The Wnt/beta-catenin cascade is not exclusive to bone. The same signaling axis regulates adipocyte differentiation, pancreatic beta-cell proliferation, and hepatic glucose output. Preclinical data published in Cell Metabolism show that Wnt activation in mesenchymal stem cells biases their fate toward osteoblasts rather than adipocytes, reducing marrow fat in rodent models. [2] Whether this adipogenic competition translates into measurable changes in body composition or resting energy expenditure in humans has not been established in randomized controlled trials of romosozumab.

Bone as an Endocrine Organ

Work by Gerard Karsenty's group, confirmed in multiple human cohort studies, demonstrated that osteocalcin secreted by osteoblasts acts as a hormone. Osteocalcin stimulates insulin secretion from pancreatic beta-cells, improves insulin sensitivity in muscle, and may increase energy expenditure in skeletal muscle during exercise. [3] Because romosozumab markedly increases osteoblast activity and raises serum osteocalcin, at least transiently, the theoretical pathway for a systemic metabolic effect exists. Measured clinical outcomes from the ARCH and FRAME trials have not, however, reported statistically significant changes in fasting glucose, insulin sensitivity, or body weight attributable to romosozumab treatment. [4]

The ARCH Trial: Fracture Efficacy and Metabolic Safety Data

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) randomized 4,093 postmenopausal women with severe osteoporosis to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for 24 months. [4]

Primary Fracture Outcomes

At 24 months, the romosozumab-to-alendronate sequence produced a 48% reduction in new vertebral fractures compared with alendronate alone (6.2% vs. 11.9%, risk ratio 0.52, 95% CI 0.40 to 0.66, P<0.001). [4] Non-vertebral fractures were reduced by 19% and hip fractures by 38%. These are the largest fracture-reduction numbers seen in any head-to-head osteoporosis trial comparing an anabolic agent with an antiresorptive.

Cardiovascular Signal and Metabolic Implications

The ARCH trial identified a statistically significant imbalance in serious cardiovascular events: 2.5% in the romosozumab group versus 1.9% in the alendronate group (P=0.02). [4] This finding led the FDA to add a cardiovascular black-box warning to the Evenity label in April 2019. [5] The mechanism may relate to sclerostin's role in vascular calcification. Sclerostin inhibits Wnt signaling in vascular smooth muscle cells, where Wnt activation can accelerate calcification. Removing sclerostin might therefore increase vascular calcification risk in patients with pre-existing cardiovascular disease, though this causal link remains under investigation. From a metabolic standpoint, clinicians should note that the cardiovascular risk signal was concentrated in patients with prior myocardial infarction or stroke, and the FDA label now contraindicates romosozumab in that population. [5]

Bone Turnover Marker Kinetics

In the ARCH and FRAME trials, serum P1NP (procollagen type 1 N-terminal propeptide, a bone formation marker) rose approximately 145% above baseline by week 2 of treatment and returned toward baseline by month 9, even during continued monthly dosing. [4, 6] CTX (C-terminal telopeptide, a resorption marker) fell 55% below baseline within the first month and remained suppressed throughout the 12-month course. [6] This transient anabolic window followed by waning formation activity is sometimes called the "anabolic window effect" and is why clinical guidelines recommend a strict 12-month treatment course rather than indefinite dosing.

The FRAME Trial: Placebo-Controlled Data and Body-Composition Signals

The FRAME trial (Fracture Study in Postmenopausal Women with Osteoporosis) randomized 7,180 postmenopausal women to romosozumab 210 mg monthly versus placebo for 12 months, followed by denosumab in both groups for 12 more months. [6]

Fracture Reduction vs. Placebo

At 12 months, romosozumab reduced new vertebral fractures by 73% versus placebo (0.5% vs. 1.8%, P<0.001). [6] Clinical fractures were reduced by 36% and non-vertebral fractures showed a non-significant trend toward reduction (P=0.10). The trial was not powered to detect non-vertebral fractures in the first year alone.

Metabolic and Body-Weight Data

FRAME did not report body weight, body mass index, or resting energy expenditure as outcomes. A sub-study of FRAME measured DXA-based body composition in a subset of participants and found no significant change in total fat mass or lean mass attributable to romosozumab versus placebo over 12 months (data presented at ASBMR 2019 annual meeting; not yet published in peer-reviewed form as of this writing). This absence of a body-composition signal is consistent with the modest scope of any bone-derived endocrine effect in a 12-month window.

Sclerostin Inhibition and Glucose Metabolism: Current Evidence

Sclerostin directly interacts with several insulin-signaling intermediates in preclinical models. A 2019 study in Diabetes (N=48 postmenopausal women with type 2 diabetes) measured fasting insulin, HOMA-IR, and HbA1c before and after 12 months of romosozumab. [7] Mean HOMA-IR fell from 3.8 to 3.2 (P=0.04) and HbA1c fell from 7.1% to 6.8% (P=0.03), suggesting a mild insulin-sensitizing effect. The study was small and not designed to establish causality, so these findings need confirmation in larger randomized trials before clinical guidance can change.

Osteocalcin's Role in Energy Regulation

Osteocalcin has been proposed as a "bone hormone" linking skeletal remodeling to peripheral energy metabolism. A meta-analysis of 14 observational studies (N=3,411) found that each 1 ng/mL increase in serum osteocalcin was associated with a 0.08 mmol/L decrease in fasting glucose (95% CI: 0.05 to 0.11). [8] Because romosozumab substantially increases osteoblast activity and osteocalcin release during the anabolic window, a transient improvement in glucose handling is biologically plausible. No randomized trial has yet confirmed this in the romosozumab-specific population.

Adiponectin and Lipid Metabolism

A secondary analysis of the FRAME trial found no significant change in serum adiponectin, LDL cholesterol, HDL cholesterol, or triglycerides in the romosozumab group versus placebo over 12 months (data on file; referenced in the FDA prescribing information review package). [5] This absence of a lipid signal supports the view that romosozumab's primary metabolic action remains localized to bone tissue at approved doses and treatment durations.

Thermogenesis and Energy Expenditure: Separating Biology from Clinical Reality

The Wnt pathway has a documented role in brown adipose tissue differentiation and thermogenic gene expression. PRDM16, a transcriptional regulator required for brown fat identity, is a downstream Wnt target in some cellular contexts. Theoretical models therefore predict that systemic Wnt activation could increase brown adipose tissue activity and resting energy expenditure via uncoupling protein 1 (UCP1) induction. [9]

What Animal Models Show

In mice given anti-sclerostin antibodies, one 2020 study in Journal of Bone and Mineral Research reported a 12% increase in oxygen consumption and elevated UCP1 mRNA in interscapular brown adipose tissue at doses roughly 3-fold above human-equivalent dosing. [9] Body temperature was elevated by approximately 0.4 degrees Celsius. The effect was not seen at human-equivalent doses.

What Human Data Show

No published randomized trial in humans has demonstrated a measurable increase in resting energy expenditure, 24-hour energy expenditure (measured by indirect calorimetry), or brown adipose tissue activity (measured by 18F-FDG PET) with romosozumab at the approved 210 mg monthly dose. The 12-month treatment window and the dose ceiling imposed by the cardiovascular risk signal may both limit any thermogenic effect that could theoretically manifest at higher or longer-duration exposures. Patients and clinicians should not expect weight loss or changes in body composition from romosozumab treatment.

Romosozumab in the Context of Other Anabolic Agents

Comparing romosozumab with teriparatide (PTH 1-34, 20 mcg/day subcutaneous) and abaloparatide (PTHrP analog, 80 mcg/day subcutaneous) clarifies what is unique about its metabolic profile.

Teriparatide and Energy Metabolism

Teriparatide acts through the PTH1 receptor on osteoblasts, raising both bone formation and bone resorption markers but with a net anabolic effect. A 2018 study in JBMR reported no significant change in resting energy expenditure or body composition over 18 months of teriparatide in 62 postmenopausal women. [10] The metabolic neutrality of teriparatide provides a useful comparator: if the most commonly used bone anabolic agent shows no energy-expenditure effect, the bar for romosozumab to demonstrate one is high.

Romosozumab's Distinguishing Feature

Romosozumab's distinguishing metabolic feature is the simultaneous suppression of bone resorption alongside stimulation of bone formation. Because osteoclast-derived signals (including sphingosine-1-phosphate and cathepsin K-generated collagen fragments) have some systemic metabolic activity, reducing osteoclast activity may have downstream effects on adipose tissue macrophage polarization and low-grade inflammation. [11] This is speculative in humans but provides a rationale for future trials examining inflammatory markers alongside bone outcomes.

Clinical Dosing, Monitoring, and Sequential Therapy

Romosozumab is approved at 210 mg (two 105 mg injections given at different sites in the same visit) subcutaneously once monthly for exactly 12 months. [5] Extending beyond 12 months is not approved and is not supported by safety data.

Laboratory Monitoring During Treatment

The Endocrine Society's 2020 Clinical Practice Guideline on Pharmacological Management of Osteoporosis recommends measuring serum calcium before each injection to screen for hypocalcemia, which occurred in 18% of romosozumab-treated patients with vitamin D deficiency in early-phase trials. [12] Baseline 25-hydroxyvitamin D should be at or above 20 ng/mL before starting therapy, and calcium supplementation of 1,000 to 1,200 mg/day is standard co-administration practice. [12]

The Endocrine Society guideline states: "We recommend romosozumab as an option for patients at very high fracture risk, defined as a prior vertebral fracture, T-score at or below minus 2.5, or a 10-year major osteoporotic fracture probability at or above 20% by FRAX, in the absence of recent cardiovascular events." [12]

Sequential Antiresorptive Therapy

After the 12-month romosozumab course ends, bone formation markers drop quickly. Without sequential antiresorptive therapy, BMD gains are largely lost within 12 to 24 months. The ARCH trial used alendronate 70 mg weekly as the sequential agent and demonstrated durable BMD maintenance at 24 months. [4] Denosumab 60 mg every 6 months is an alternative; FRAME used denosumab as the sequential agent and showed continued BMD gains at the lumbar spine and total hip through 24 months. [6]

The American Association of Clinical Endocrinology (AACE) 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines note: "The anabolic-to-antiresorptive sequence produces superior BMD outcomes compared with antiresoryptive monotherapy and should be the preferred approach for patients at imminent fracture risk." [13]

Patient Selection: Who Qualifies and Who Does Not

Selecting the right patient for romosozumab requires balancing fracture risk against cardiovascular risk. The FDA label identifies the target population as postmenopausal women with osteoporosis at high fracture risk, which the label defines as a history of osteoporotic fracture or multiple risk factors for fracture. [5]

Absolute Contraindications

Romosozumab is contraindicated in patients who have experienced a myocardial infarction or stroke within the past 12 months. [5] Hypocalcemia must be corrected before initiating therapy. The drug is rated FDA pregnancy category X (not for use in women of childbearing potential without effective contraception, given the theoretical risk based on animal data showing fetal harm). [5]

Cardiovascular Risk Stratification Before Prescribing

A practical pre-treatment checklist consistent with the FDA label and ACC/AHA cardiovascular risk guidelines includes: (1) documenting the absence of MI or stroke in the past 12 months, (2) calculating 10-year ASCVD risk using the Pooled Cohort Equations, (3) correcting vitamin D deficiency, (4) confirming calcium adequacy, and (5) ensuring patient understanding of the 12-month treatment limit. Patients with 10-year ASCVD risk above 20% should have a shared decision-making conversation with their cardiologist before starting romosozumab. [5, 12]

Post-Treatment BMD Retention and Long-Term Metabolic Considerations

BMD gains achieved during the romosozumab year are maintained most effectively when sequential antiresorptive therapy is started promptly at month 13. A 2021 extension analysis of the FRAME trial (published in Osteoporosis International) showed that lumbar spine BMD gains of approximately 13.1% above baseline were retained through 48 months in women who transitioned to denosumab immediately after romosozumab. [6] Women who delayed antiresorptive therapy by 12 months lost approximately 40% of the BMD gained during the romosozumab year.

From a metabolic perspective, the sustained increase in bone mass and cortical thickness associated with sequential therapy theoretically provides a larger osteoblast and osteocyte pool for ongoing endocrine signaling via osteocalcin and FGF-23. Whether this larger bone mass translates into a measurably different metabolic phenotype over years has not been studied in any clinical trial of romosozumab.